Assessment of Tp-e interval and Tp-e/QT ratio in patients with human immunodeficiency virus.


Journal

Revista portuguesa de cardiologia
ISSN: 2174-2049
Titre abrégé: Rev Port Cardiol (Engl Ed)
Pays: Spain
ID NLM: 101770878

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 06 06 2018
revised: 29 03 2019
accepted: 07 04 2019
pubmed: 21 4 2020
medline: 21 4 2021
entrez: 21 4 2020
Statut: ppublish

Résumé

Sudden cardiac death (SCD) plays an important part in all-cause mortality in patients infected with human immunodeficiency virus (HIV). The T-peak to T-end (Tp-e) interval, corrected Tp-e (Tp-ec) interval, and Tp-e/QT ratio on the ECG are parameters used to stratify risk for SCD. The objective of this study was to investigate the differences between HIV-infected patients and healthy individuals in terms of Tp-e interval, Tp-ec interval, and Tp-e/QT ratio, as well as other influencing factors. Ninety-eight HIV-infected patients and 62 healthy controls were included in this prospective case-control study. Tp-e interval, Tp-ec interval, and Tp-e/QT ratio were measured in all participants. Echocardiographic examination and routine laboratory analysis were performed. In addition, CD4 T-cell count and HIV RNA levels were assessed in HIV-infected patients. All baseline characteristics were comparable in both groups. The median survival of those living with HIV was 20.63 months; 53% of them had controlled viral load, and 74% were receiving antiretroviral therapy. Mean baseline CD4 T-cell count was 409. In HIV-infected patients, the Tp-e interval and Tp-ec interval were prolonged, and the Tp-e/QT ratio was higher (p<0.001, p<0.001 and p=0.021, respectively). In bivariate and partial correlation analyses, there was a negative correlation between CD4 T-cell level and Tp-e interval, Tp-ec interval, and Tp-e/QT ratio. Tp-e interval, Tp-ec interval, and Tp-e/QT ratio were greater in HIV-infected patients compared with healthy individuals. HIV-infected patients, particularly those with low baseline CD4 T-cell counts, should be closely monitored due to risk of SCD.

Identifiants

pubmed: 32307210
pii: S0870-2551(20)30125-6
doi: 10.1016/j.repc.2019.04.010
pii:
doi:

Types de publication

Journal Article

Langues

eng por

Sous-ensembles de citation

IM

Pagination

155-160

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. All rights reserved.

Auteurs

Sukru Cetin (S)

Department of Cardiology, Sancaktepe Şehit Prof İlhan Varank Training and Research Hospital, Istanbul, Turkey. Electronic address: chetinsukru@hotmail.com.

Ayşe Şabablı Çetin (AŞ)

Department of Infectious Diseases and Clinical Microbiology, Sancaktepe Şehit Prof İlhan Varank Training and Research Hospital, Istanbul, Turkey.

Ahmet Gurdal (A)

Department of Cardiology Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey.

Süleyman Sezai Yıldız (SS)

Department of Cardiology Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey.

Kudret Keskin (K)

Department of Cardiology Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey.

Serhat Sığırcı (S)

Department of Cardiology Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey.

Ali Bayraktar (A)

Department of Cardiology, Sancaktepe Şehit Prof İlhan Varank Training and Research Hospital, Istanbul, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH